Deciphera Pharmaceuticals (Deciphera Pharmaceuticals) EBIT : $-211.0 Mil (TTM As of Dec. 2023)

View and export this data going back to 2017. Start your Free Trial

What is Deciphera Pharmaceuticals EBIT?

Deciphera Pharmaceuticals's earnings before interest and taxes (EBIT) for the three months ended in Dec. 2023 was $-51.2 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2023 was $-211.0 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Deciphera Pharmaceuticals's annualized ROC % for the quarter that ended in Dec. 2023 was -173.73%. Deciphera Pharmaceuticals's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -535.35%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Deciphera Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -11.69%.

Deciphera Pharmaceuticals EBIT Historical Data

The historical data trend for Deciphera Pharmaceuticals's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Deciphera Pharmaceuticals EBIT Chart

Deciphera Pharmaceuticals Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT

Get a 7-Day Free Trial

-192.19

-271.19

-300.08

-182.72

-210.96

Deciphera Pharmaceuticals Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EBIT	Get a 7-Day Free Trial															-47.16	-53.26	-52.78	-53.69	-51.24

Competitive Comparison of Deciphera Pharmaceuticals's EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, Deciphera Pharmaceuticals's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Deciphera Pharmaceuticals's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Deciphera Pharmaceuticals's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Deciphera Pharmaceuticals's EV-to-EBIT falls into.

Deciphera Pharmaceuticals EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-211.0 Mil.

Deciphera Pharmaceuticals (NAS:DCPH) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Deciphera Pharmaceuticals's annualized ROC % for the quarter that ended in Dec. 2023 is calculated as:

	ROC % (Q: Dec. 2023 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Sep. 2023 )	+	Invested Capital (Q: Dec. 2023 ))	/ count )
=	-204.952 * ( 1 - -0.92% )	/	( (114.124	+	123.986)	/ 2 )
=	-206.8375584	/	119.055
=	-173.73 %

where

	Invested Capital		(Q: Sep. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	497.836	-	59.03	-	( 339.075	-	max(0, 92.894	-	417.576	+	339.075	))
=	114.124

	Invested Capital		(Q: Dec. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	473.566	-	68.759	-	( 306.216	-	max(0, 100.275	-	381.096	+	306.216	))
=	123.986

Note: The Operating Income data used here is four times the quarterly (Dec. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

Deciphera Pharmaceuticals's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Dec. 2023 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Sep. 2023		Q: Dec. 2023
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-204.952	/	( ( (39.073 + max(-10.957, 0))	+	(37.494 + max(-21.891, 0)) )	/	2 )
=	-204.952	/	( ( 39.073	+	37.494 )	/	2 )
=	-204.952	/	38.2835
=	-535.35 %

where Working Capital is:

	Working Capital		(Q: Sep. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(27.549	+	27.105	+	23.847)	-	(59.03	+	0	+	30.428)
=	-10.957

	Working Capital		(Q: Dec. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(31.952	+	21.21	+	21.718)	-	(68.759	+	0	+	28.012)
=	-21.891

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Deciphera Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Dec. 2023 )
	=	-210.958	/	1804.914
	=	-11.69 %

Deciphera Pharmaceuticals EBIT Related Terms

Thank you for viewing the detailed overview of Deciphera Pharmaceuticals's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Deciphera Pharmaceuticals (Deciphera Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Deciphera Pharmaceuticals Inc (NAS:DCPH) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

D05:Germany

Address

200 Smith Street, Waltham, MA, USA, 02451

Website

https://www.deciphera.com

Deciphera Pharmaceuticals Inc is a biotechnology company, which develops and manufactures kinase-inhibiting drugs for the treatment of cancers and immunological diseases. It holds a diverse pipeline of drug candidates that includes three clinical-stage and two research-stage programs. Its lead drug candidate DCC-2618 is designed to inhibit the full spectrum of mutant or amplified KIT and Pdgfra kinases that drive cancers such as gastrointestinal stromal tumors, advanced systemic mastocytosis, gliomas, and other solid tumors. In addition, it is also developing two other clinical-stage drug candidates, DCC-3014 and Rebastinib. Geographically all the operations function through the region of the United States.

Executives

Jama Pitman	officer: SVP, Regulatory & Quality	C/O DECIPHERA PHARMACEUTICALS, INC., 200 SMITH STREET, WALTHAM MA 02451
Daniel C. Martin	officer: Chief Commercial Officer	C/O DECIPHERA PHARMACEUTICALS, INC., 200 SMITH STREET, WALTHAM MA 02451
Thomas Patrick Kelly	officer: Chief Financial Officer	C/O DECIPHERA PHARMACEUTICALS, INC., 200 SMITH STREET, WALTHAM MA 02451
Matthew L Sherman	officer: EVP & Chief Medical Officer	C/O DECIPHERA PHARMACEUTICALS, INC., 200 SMITH STREET, WALTHAM MA 02451
Steven L. Hoerter	director	C/O DECIPHERA PHARMACEUTICALS, INC., 200 SMITH STREET, WALTHAM MA 02451
Dashyant Dhanak	officer: EVP & Chief Scientific Officer	C/O INCYTE CORPORATION, 1801 AUGUSTINE CUT-OFF, WILMINGTON DE 19803
Daniel Lee Flynn	officer: Chief Scientific Officer	C/O DECIPHERA PHARMACEUTICALS, INC., 200 SMITH STREET, WALTHAM MA 02451
Franklin Stuart Friedman	director	C/O DECIPHERA PHARMACEUTICALS, INC., 200 SMITH STREET, WALTHAM MA 02451
Dennis Leo Walsh	director	C/O DECIPHERA PHARMACEUTICALS, INC., 200 SMITH STREET, WALTHAM MA 02451
Brightstar Associates Llc	10 percent owner	1020 CENTRAL STREET, KANSAS CITY MO 64105
James Arthur Bristol	director	C/O DECIPHERA PHARMACEUTICALS, INC., 200 SMITH STREET, WALTHAM MA 02451
Michael Douglas Taylor	director, officer: See Remarks	C/O DECIPHERA PHARMACEUTICALS, LLC, 500 TOTTEN POND ROAD, WALTHAM MA 02451
Patricia L Allen	director	C/O DECIPHERA PHARMACEUTICALS, INC, 200 SMITH STREET, WALTHAM MA 02451
Christopher John Morl	officer: Chief Business Officer	C/O DECIPHERA PHARMACEUTICALS, LLC, 500 TOTTEN POND ROAD, WALTHAM MA 02451
Ron Squarer	director	C/O ADC THERAPEUTICS SA, BIOPOLE, ROUTE DE LA CORNICHE 3B, EPALINGES V8 1066